Frontiers in Molecular Neuroscience, published by FRONTIERS MEDIA SA, is an esteemed open-access journal dedicated to advancing our understanding of the molecular mechanisms underlying neurological functions and disorders. Since its inception in 2008, the journal has established itself as a reputable source of cutting-edge research, earning a respectable Q2 ranking in both the fields of Cellular and Molecular Neuroscience and Molecular Biology as of 2023. With an ongoing commitment to fostering innovation, the journal presents a platform for researchers, professionals, and students to disseminate their findings and engage in scholarly discourse. The E-ISSN 1662-5099 ensures that research is readily accessible, facilitating the exchange of knowledge crucial to tackling the complexities of neurological conditions. Situated in Switzerland, the journal’s global reach is augmented by its open-access model, allowing for wide dissemination of critical research findings to a diverse audience. Join the vibrant community of scientists and practitioners who are shaping the future of molecular neuroscience through their contributions to this dynamic journal.

MOLECULAR THERAPY, published by CELL PRESS, is a distinguished journal in the field of molecular biology and therapy, renowned for its significant contributions to drug discovery, genetics, and pharmacology since its inception in 2000. This prestigious journal, which holds a commendable position in the Q1 category across multiple disciplines including Drug Discovery, Molecular Medicine, and Molecular Biology, facilitates cutting-edge research and innovative therapies that aim to improve patient outcomes. With an impressive Scopus ranking that places it among the top journals in its field—such as rank #6 in Drug Discovery and #8 in Pharmacology—MOLECULAR THERAPY is crucial for researchers, professionals, and students seeking to advance their understanding and application of molecular techniques. The journal welcomes high-quality submissions that explore the therapeutic potential of molecular mechanisms, fostering a collaborative spirit within the scientific community to push the boundaries of modern medicine.

Purinergic Signalling, published by Springer, is a pivotal academic journal dedicated to the exploration of purinergic signaling pathways and their implications in various biological processes. Since its inception in 2004, the journal has made significant contributions to the fields of Cell Biology, Cellular and Molecular Neuroscience, and Molecular Biology, consistently ranking in the Q3 category in recent assessments. With a strong focus on the molecular mechanisms of purines and their roles in physiology and pathology, Purinergic Signalling serves as an essential resource for researchers and professionals seeking to understand the complexity of cellular communication. Although it does not offer open access, the journal ensures a broad dissemination of high-quality research findings, making it a vital tool for academic advancement in the fields of neuroscience and molecular biology. Its commitment to scholarly excellence is reflected in its Scopus rankings, where it is competitively positioned within its categories. As we approach its 20th anniversary in 2024, Purinergic Signalling continues to inspire and inform cutting-edge research in the dynamic landscape of life sciences.

FOLIA NEUROPATHOLOGICA is a distinguished Open Access journal specializing in the fields of Neurology and Pathology, published by the reputable TERMEDIA PUBLISHING HOUSE LTD. With an ISSN of 1641-4640 and E-ISSN 1509-572X, this journal has been a vital resource for the dissemination of high-quality research since its inception in 1994. Covering a broad spectrum of topics within neuropathology, the journal emphasizes clinical findings and forensic implications, making it an essential platform for healthcare professionals, researchers, and students alike. With impressive impact factors positioning it in the Q3 category for both Neurology (clinical) and Pathology and Forensic Medicine, FOLIA NEUROPATHOLOGICA occupies a significant place among its peers, ranked within the 36th to 46th percentiles on Scopus. Scholars can benefit from the Open Access model implemented since 2005, ensuring wide accessibility and distribution of critical research outputs aimed at advancing both clinical practices and academic knowledge. Based in Poland, at KLEEBERGA 2, POZNAN 61-615, this journal continues to shape the discourse in neuropathology and related fields.

The Annual Review of Neuroscience, published by Annual Reviews, is a premier journal that has been at the forefront of neuroscience research since its inception in 1978. With an ISSN of 0147-006X and E-ISSN 1545-4126, this leading academic journal boasts a remarkable impact factor, placing it in the prestigious Q1 category in Neuroscience (miscellaneous), with an impressive Scopus ranking of 4 out of 113 and a stellar 96th percentile in general neuroscience. Focused on publishing comprehensive and authoritative review articles, the Annual Review of Neuroscience aims to synthesize and critically evaluate the latest advances in the field, making it an indispensable resource for researchers, professionals, and students alike. While it does not offer open access, the insights and discoveries highlighted in its issues are crucial for those dedicated to understanding the complexities of the nervous system and driving forward innovative research. With a commitment to excellence and a forward-looking perspective, this journal continues to shape and influence the future of neuroscience.

Translational Neurodegeneration, an esteemed journal in the field of neuroscience, is published by BMC and has been an open access platform since 2012, delivering high-quality research from its base in the United Kingdom. With an impressive impact factor reflecting its significant contributions, this journal focuses on critical advancements in cellular and molecular neuroscience, cognitive neuroscience, and clinical neurology, boasting a Q1 ranking across all these categories as of 2023. Researchers and professionals benefit from its extensive reach, characterized by exceptional Scopus rankings that place it in the top percentile of its field. The journal serves as a vital resource for academics and healthcare practitioners alike, aiming to bridge the gap between laboratory discoveries and clinical applications, thereby enhancing understanding and treatment of neurodegenerative diseases. With its commitment to open access, Translational Neurodegeneration ensures that its published research is accessible to a global audience, promoting collaboration and knowledge exchange within the scientific community.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

Molecular Neurodegeneration is a leading journal published by BMC, dedicated to advancing the field of neurodegeneration through high-quality, open-access research. Since its inception in 2006, this peer-reviewed journal has provided a pivotal platform for the dissemination of innovative findings in the realms of Cellular and Molecular Neuroscience, Molecular Biology, and Clinical Neurology. With a stellar impact factor and listed in the prestigious Q1 category in multiple relevant categories, it ranks among the top publications in the field—specifically, it holds the #3 position in Neuroscience and #6 position in Clinical Neurology based on Scopus metrics. Researchers, professionals, and students alike will find significant value in the open access format, which fosters unrestricted sharing of knowledge, ensuring that emerging ideas in neurodegeneration reach a global audience. Based in London, United Kingdom, the journal promises a comprehensive scope that addresses critical questions in neurobiology, making it an essential resource for anyone interested in the molecular mechanisms underlying neurodegenerative diseases.

NEUROPATHOLOGY, an esteemed journal published by WILEY, is a pivotal platform in the fields of medicine and neurology, focusing on the intricate relationship between pathology and neurological disorders. Established in 1993 and continually evolving until 2024, the journal holds a notable presence within the academic community, as evidenced by its current Q2 ranking in several categories including Medicine (Miscellaneous), Neurology (Clinical), and Pathology and Forensic Medicine. With a Scopus ranking placing it within the top 30% of its field, NEUROPATHOLOGY serves as a vital resource for researchers, healthcare professionals, and students dedicated to advancing their knowledge of neuropathological processes. Although not an Open Access journal, it ensures accessibility to cutting-edge research and insights that shape contemporary understanding and clinical practice. Its robust impact factor underscores the journal's critical role in disseminating innovative findings within the realms of neurology and pathology, making it an essential read for those at the forefront of medical research.

FASEB BioAdvances, published by WILEY, is an esteemed open-access journal dedicated to advancing the fields of biochemistry, molecular biology, and physiology. Since its inception in 2019, the journal has rapidly established a significant presence within the academic community, boasting an impressive impact factor reflective of its Q2 and Q3 standings across various categories, including Biochemistry, Genetics and Molecular Biology, Cancer Research, Molecular Medicine, and Physiology. The journal aims to disseminate high-quality research and innovative findings to enhance the understanding of biological processes, making it a vital resource for researchers, professionals, and students alike. With its commitment to open access, FASEB BioAdvances ensures that groundbreaking research is available to a global audience, facilitating collaboration and exploration in these rapidly evolving scientific domains.